Jump to content

Oxcarbazepine: Difference between revisions

From Pharmacopedia
[checked revision][checked revision]
← Older edit

MDElliottMD (talk | contribs)

3 user groups
5,189 edits
VisualWikitext
Dedupe migration per interface-claude 2026-05-20: Anticonvulsants / Antiepileptics merged into canonical Anticonvulsants. Member retagged.
parser-claude: Oxcarbazepine MedTemplate refill, Top 300 stub upgrade
 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{MedTemplate
{{MedTemplate
| generic           = Oxcarbazepine
| generic           = Oxcarbazepine
| brand             = Trileptal
| brand             = Trileptal (IR), Oxtellar XR
| structure         =  
| structure         =
| classes           = Mood Stabilizer, Anticonvulsant
| classes           = [[:Category:Anticonvulsants|Anticonvulsant]], [[:Category:Mood stabilizers|Mood stabilizer (off-label)]], [[:Category:Sodium channel blockers|Sodium channel blocker]]
| mechanism          = Sodium channel blocker
| uses             = <vote slug="partial-seizures-monotherapy-use">Partial-onset seizures (FDA, adult monotherapy and adjunct, pediatric ≥2)</vote>, <vote slug="trigeminal-neuralgia-use">Trigeminal neuralgia (off-label, often preferred over carbamazepine for better tolerability)</vote>, <vote slug="bipolar-disorder-oxcarbazepine-use">Bipolar I disorder (off-label, similar utility to carbamazepine)</vote>
| uses               =  
| starting_dose     = Adult monotherapy: 300 mg PO BID, titrate by 300 mg every 3 days. Pediatric: weight-based titration starting 8-10 mg/kg/day divided BID
| starting_dose     =  
| preparations     = IR tablets 150, 300, 600 mg; oral suspension 60 mg/mL; XR tablets 150, 300, 600 mg (Oxtellar)
| preparations       =  
| fda_max           = 2400 mg/day (adult)
| fda_max          =  
| pill_id           =
| routes             =  
| routes           = Oral
| onset             =  
| onset             = Anticonvulsant effect within days at therapeutic plasma level
| duration           =  
| duration         = BID dosing (IR); once-daily (XR)
| halflife           =  
| halflife         = Oxcarbazepine 2 hours; '''10-monohydroxy active metabolite (MHD) ~9 hours''' (the agent that produces essentially all of the clinical effect)<ref name="trileptal-label">FDA Prescribing Information, Trileptal (oxcarbazepine), Novartis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021014s036lbl.pdf</ref>
| bioavailability   =  
| bioavailability   = ~100% (oral)<ref name="trileptal-label" />
| pregnancy         =  
| pregnancy         = Teratogenic signal less than carbamazepine but present; folate supplementation and effective contraception are appropriate in reproductive-age patients<ref name="trileptal-label" />
| legal             =  
| legal             = [[USLegal:Prescription only|Rx-only]] in US
| intro              =
| mechanism        = <vote slug="oxcarbazepine-mech-claim">The 10-monohydroxy active metabolite (MHD) is the clinically active species, a voltage-gated sodium channel blocker in the inactivated state. Compared to its parent compound carbamazepine, oxcarbazepine has '''substantially less CYP3A4 autoinduction''', fewer cytochrome-mediated interactions, no clinically significant aplastic anemia or agranulocytosis signal, and a cleaner overall tolerability profile.</vote> '''Retains the HLA-B*15:02 cross-sensitivity''' of carbamazepine for Stevens-Johnson syndrome and toxic epidermal necrolysis risk in Asian populations; CPIC and FDA recommend pre-treatment HLA-B*15:02 testing. '''Hyponatremia''' is more common than with carbamazepine, particularly in elderly patients; sodium monitoring during titration is standard<ref name="cpic-hla">CPIC Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine, 2017. https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/</ref>.
| pharmacokinetics  =  
| pharmacodynamics  =  
| indications        =
| dosing            =
| effects            =
| interactions       = <pharmaInteractions/>
| pregnancy_details  =
| monitoring         =
| counseling        =
| anecdotes          =
| seealso            =
| references        =  
}}
}}


[[Category:Mood_Stabilizers]]
== References ==
<references />
 
[[Category:Anticonvulsants]]
[[Category:Mood stabilizers]]
[[Category:Sodium channel blockers]]
[[Category:Sodium channel blockers]]
[[Category:Anticonvulsants]]
[[Category:Mood Stabilizers]]

Latest revision as of 07:24, 23 May 2026

Anticonvulsant, Mood stabilizer (off-label), Sodium channel blocker
Oxcarbazepine
Trileptal (IR), Oxtellar XR

Experience

👥 No personal reports yet
⚕ No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Anticonvulsant, Mood stabilizer (off-label), Sodium channel blocker
Common uses
Partial-onset seizures (FDA, adult monotherapy and adjunct, pediatric ≥2)0, Trigeminal neuralgia (off-label, often preferred over carbamazepine for better tolerability)0, Bipolar I disorder (off-label, similar utility to carbamazepine)0
Pharmacy
Starting dose
Adult monotherapy: 300 mg PO BID, titrate by 300 mg every 3 days. Pediatric: weight-based titration starting 8-10 mg/kg/day divided BID
Preparations
IR tablets 150, 300, 600 mg; oral suspension 60 mg/mL; XR tablets 150, 300, 600 mg (Oxtellar)
US FDA Max
2400 mg/day (adult)
Pharmacology
Routes
Oral
Onset
Anticonvulsant effect within days at therapeutic plasma level
Duration
BID dosing (IR); once-daily (XR)
Half-life
Oxcarbazepine 2 hours; 10-monohydroxy active metabolite (MHD) ~9 hours (the agent that produces essentially all of the clinical effect)[2]
Bioavailability
~100% (oral)[2]
Pregnancy
Teratogenic signal less than carbamazepine but present; folate supplementation and effective contraception are appropriate in reproductive-age patients[2]
Legal status
Rx-only in US
Purported mechanism
The 10-monohydroxy active metabolite (MHD) is the clinically active species, a voltage-gated sodium channel blocker in the inactivated state. Compared to its parent compound carbamazepine, oxcarbazepine has substantially less CYP3A4 autoinduction, fewer cytochrome-mediated interactions, no clinically significant aplastic anemia or agranulocytosis signal, and a cleaner overall tolerability profile.0 Retains the HLA-B*15:02 cross-sensitivity of carbamazepine for Stevens-Johnson syndrome and toxic epidermal necrolysis risk in Asian populations; CPIC and FDA recommend pre-treatment HLA-B*15:02 testing. Hyponatremia is more common than with carbamazepine, particularly in elderly patients; sodium monitoring during titration is standard[1].

References

  1. ↑ CPIC Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine, 2017. https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/
  2. ↑ 2.0 2.1 2.2 FDA Prescribing Information, Trileptal (oxcarbazepine), Novartis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021014s036lbl.pdf
Retrieved from "https://pharmacopedia.wiki/index.php?title=Oxcarbazepine&oldid=6717"